Clinical Trials
23 trialsNCT07530445 2026-04-15
Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT07108114 2026-02-23
SLV-324 Treatment of Metastatic Solid Tumors
Solve Therapeutics
Phase 1 Recruiting
NCT07286253 2025-12-16
QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Recruiting
NCT07272590 2025-12-09
Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07243691 2025-11-24
Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
Sir Run Run Shaw Hospital
Phase NA Recruiting
NCT06490718 2025-09-08
Comparing Quality of Recovery Between ESPB and IV Lidocaine After Major Breast Cancer Surgery
Chinese University of Hong Kong
Phase NA Completed
NCT06505837 2025-08-28
JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Active not recruiting
NCT03850574 2025-08-26
TUSCANY
Aptose Biosciences Inc.
Phase 1/2 Recruiting
NCT05894889 2025-07-23
Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC
Peking University
Phase 2 Active not recruiting
NCT07024030 2025-06-17
DGPR1008
The Affiliated Hospital of Qingdao University
Phase 2 Completed
NCT03238248 2024-11-04
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT04477772 2024-05-16
A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Completed
NCT06330337 2024-03-26
Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma
The Third Affiliated hospital of Zhejiang Chinese Medical University
Phase 3 Recruiting
NCT06232694 2024-01-31
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
The First Affiliated Hospital with Nanjing Medical University
Phase NA Recruiting
NCT05053308 2023-08-07
Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement
Seoul National University
Phase NA Withdrawn
NCT05798533 2023-07-10
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
BGI, China
Phase 1 Unknown
NCT05798546 2023-04-04
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
BGI, China
Phase 1 Unknown
NCT05448599 2023-03-15
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT05524194 2022-09-01
6MW3511 in Patients With Advanced Solid Tumor
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT05001451 2022-07-20
Study of GDX012 in Patients With MRD Positive AML
GammaDelta Therapeutics Limited
Phase 1 Terminated
NCT05048160 2022-05-09
A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT01023958 2017-11-22
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00399035 2016-12-28
HORIZON II
AstraZeneca
Phase 3 Completed